Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ACTU
ACTU
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ACTU News
Actuate Therapeutics Announces Encouraging Phase II Results for Salivary Gland Cancers
Dec 15 2025
NASDAQ.COM
HC Wainwright & Co. Affirms Buy Rating for Actuate Therapeutics, Keeps $20 Price Target Intact
Sep 23 2025
Benzinga
Actuate Therapeutics Reveals Pricing for $15.0 Million Public Stock Offering
Sep 10 2025
Newsfilter
Actuate Therapeutics Analyst Starts Coverage Positively; Check Out Tuesday's Top 3 Initiations
Aug 26 2025
Benzinga
B. Riley Securities Begins Coverage of Actuate Therapeutics with a Buy Rating and Sets Price Target at $20
Aug 26 2025
Benzinga
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
Aug 06 2025
Newsfilter
RSSL's Underlying Holdings Imply 20% Gain Potential
Jul 11 2025
NASDAQ.COM
Actuate's Elraglusib Shows Strong Survival Benefit In Metastatic Pancreatic Cancer
Jun 24 2025
NASDAQ.COM
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
Jun 24 2025
Newsfilter
Actuate Therapeutics Reports Significant Biomarker Data from Phase 2 Trial of Elraglusib in Metastatic Pancreatic Adenocarcinoma at ASCO Annual Meeting
Jun 20 2025
NASDAQ.COM
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Jun 16 2025
Newsfilter
Actuate Therapeutics Reports Positive Phase 2 Trial Results for Elraglusib in Metastatic Pancreatic Cancer, Improving Overall Survival
May 31 2025
NASDAQ.COM
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
May 31 2025
Newsfilter
Actuate Therapeutics: Elraglusib trial meets key endpoint in pancreatic cancer
May 31 2025
SeekingAlpha
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
May 22 2025
Newsfilter
Actuate Therapeutics Reports Positive Data From Phase 2 Study Of Elraglusib In Pancreatic Cancer
May 06 2025
NASDAQ.COM
Show More News
